Rapport Therapeutics (RAPP) Corporate presentation summary

Leadership and expertise

• Executive team and board have extensive neuroscience, biotech, and pharma experience, including prior leadership at major companies and successful drug development backgrounds.

Precision neuroscience platform and pipeline

• Focus on small molecule precision medicines for neurological and psychiatric disorders, leveraging receptor associated proteins (RAPs) for high selectivity and specificity.

• Lead program RAP-219 targets TARPγ8, a forebrain-restricted AMPAR modulator, with robust Phase 2a data in drug-resistant focal onset seizures (FOS) and expansion into other indications.

• Pipeline includes programs for primary generalized tonic-clonic seizures (PGTCS), bipolar mania, chronic pain, migraine, and hearing/vestibular disorders.

RAP-219 clinical data and market opportunity

• Phase 2a trial in highly drug-resistant FOS patients showed 71% median reduction in long episodes and 78% median reduction in clinical seizures, with 24% achieving seizure freedom at 8 weeks.

• Durable efficacy and sustained exposure observed over 16 weeks, with consistent results across patient subgroups and time periods.

• RAP-219 was generally well tolerated, with mostly mild or moderate adverse events and a 10% discontinuation rate.

• FOS, PGTCS, and bipolar mania represent large, underserved markets, with RAP-219 addressing significant unmet needs and potential for multi-billion dollar revenue.